We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Rectangle Image
Product

QIAGEN’s Liquid Biopsy Portfolio – from Sample to Insight

Rectangle Image
Product

QIAGEN’s Liquid Biopsy Portfolio – from Sample to Insight

Liquid biopsy is a new, minimally invasive approach for detection of disease biomarkers and utilization in research and clinical diagnostics without the need for costly or invasive procedures. QIAGEN® offers the most comprehensive portfolio of solutions ranging from sample isolation and stabilization to bioinformatics analysis and interpretation of results. It’s about innovative solutions that cover every single step along this journey – not just technologies, but providing valuable molecular insights. QIAGEN’s liquid biopsy portfolio empowers you to sensitively, specifically and rapidly reveal meaningful insights from your samples with an efficient, streamlined and complete workflow for analyzing circulating cell-free DNA (ccfDNA), exosomes and CTCs, giving you the first step towards uncovering valuable biomarkers in your samples. As you advance to the new frontiers of liquid biopsy, QIAGEN also strives to provide you with:

Complete workflow for analyzing circulating cell-free DNA (ccfDNA). 

ccfDNA is one of the most exciting research areas for detection, monitoring and treatment of several cancers. One major challenge for ccfDNA mutation, methylation and other analysis is the low concentration of ccfDNA found in plasma/serum. Furthermore, ccfDNAs are often fragmented. To overcome these hurdles, QIAGEN has developed a complete ccfDNA liquid biopsy solution from collection and stabilization, isolation, to data analysis and interpretation.

The PAXgene® Blood ccfDNA Tubes enable you to standardize blood collection, cell preservation and isolation of ccfDNA from separated plasma. 

S_5247_PAXBloodccfDNA_V2_s.jpg


The QIAamp® Circulating NA Kit is the gold standard for isolation of circulating cell-free nucleic acids and allows you to efficiently enrich and recover small, fragmented nucleic acids from plasma, serum or urine.

This technology is available as manual and automated versions on QIAGEN’S QIAsymphony® platform.

QIAGEN is releasing a new product for NGS library preparation, the QIAseq™ cfDNA All-in-One Kit. The new library prep kit combines best-in-class cfDNA extraction and NGS library preparation to ensure optimal sample conversion at every step in your workflow and maximizes library yields.

Furthermore, the bioinformatics solutions, including the Biomedical Genomics Workbench and Ingenuity® Variant Analysis, guide you through a complete analysis of your genome, exome, targeted amplicon, transcriptome and epigenetic NGS sequencing data for results and insights you can trust.

Circulating tumor cells (CTCs) selection and detection portfolio.

Detection and molecular characterization of CTCs allows investigations beyond CTC counting. QIAGEN’s AdnaTest portfolio is a highly specific immunomagnetic cell selection system that combines an optimized antibody with highly sensitive RT-PCR technology. The system uses a combination of mRNA tumor markers (“Combination of Combinations Principle”) to ensure maximal specificity and sensitivity of molecular characterization of CTCs from whole human blood. Currently the AdnaTest portfolio includes selection and detection panels for breast, prostate, ovarian, colon cancers and kits for analysis of hormone receptor genes for estrogen and progesterone, as well as genes associated with epithelial-mesenchymal transition, cancer cell stemness and breast cancer in enriched tumor cells. 

ILLU_0246_GG_Tumor Metastasis.jpg


Enrichment and isolation of exosomes and RNA from exosomes.
 

Exosomes and other extracellular vesicles (EVs) carry signaling molecules such as protein, mRNA and miRNA to serve as vehicles for cell-cell communication, transferring biological information in various pathophysiological processes. These cargoes carried in exosomes and EVs are actively been investigated as circulating biomarkers for cancer and other human diseases. The current isolation approach using ultracentrifugation is time-consuming. In association with Exosome Diagnostics, QIAGEN has developed a fast and convenient spin-column procedure to isolate exosomes and total RNA from exosomes and other EVs. With the exoEasy Maxi Kit, you can easily get intact exosomes in just 25 minutes, while the exoRNeasy Kits provide a novel, efficient workflow for isolation of RNAs from exosomes and other EVs in 1 hour from  a range of fluid samples. 

ILLU_0921_Exosomes_V2.jpg

Company Details
Qiagen
Strasse 1
Hilden
40724
Germany
Tel: +49 02103 29 12000
Fax: +49 02103 29 22000
Advertisement